News

Being overweight does not worsen nerve function in people with Charcot–Marie–Tooth Disease type 1A (CMT1A), but it may lead to more pain and less muscle strength in lower extremities, a study reports. Researchers published the study in the Journal of Clinical Neurophysiology. Its title is “Charcot–Marie–Tooth Disease Type 1A: Influence of Body…

Researchers have found that disease progression in Charcot-Marie-Tooth type 1A (CMT1A) patients reaches a critical point at age 50, after which clinical decline occurs faster. In response, patients should be encouraged to engage in a healthy and active lifestyle in order to preserve their function, a new study…

Melatonin can significantly decrease inflammation and oxidative stress markers that may be related to the progression of Charcot-Marie-Tooth disease, a Spanish study reports. The study, which appeared in the journal Molecules, was titled “Melatonin Treatment Reduces Oxidative Damage and Normalizes Plasma Pro-Inflammatory Cytokines in Patients Suffering from Charcot-Marie-Tooth Neuropathy:…

More therapies are now available for the 30 million or so people with rare diseases in the U.S. than ever before, and millions of dollars are being invested in clinical studies that will test new ways of evaluating — and advancing — potential treatments, including the use of natural history…

The connection between artist Andrew Wyeth’s most famous painting, Christina’s World, and Charcot-Marie-Tooth (CMT), a group of inherited disorders of the peripheral nervous system, will unfold as the Charcot-Marie-Tooth Association (CMTA) hosts its 8th Annual CMTA Gala to raise funds for clinical trials of…

As Congress begins debate this week to overhaul the U.S. tax code, lawmakers should leave the Orphan Drug Act (ODA) — and the tax incentives it offers pharmaceutical companies to develop therapies for rare diseases — off the table. That’s the message being pushed by the National Organization for…

Flex Pharma has initiated its Phase 2 COMMIT trial to evaluate the drug candidate FLX-787 in patients with Charcot-Marie-Tooth (CMT) disease who have debilitating muscle cramps. The COMMIT study (NCT03254199) is a randomized, double-blind, trial that will be conducted at 20 centers the U.S. under Flex Pharma’s open investigational…

Five case reports of patients with Charcot-Marie-Tooth disease type 4C (CMT4C) and uncommon clinical manifestations provide new insights into the complexity of this disease and demonstrate its clinical variability. The case reports were featured in an article published in the journal Muscle & Nerve. CMT4C is caused by…

Cure CMT4J, a nonprofit foundation started by a  family whose daughter was diagnosed with Charcot Marie Tooth Type 4, or CMT4J, several years ago, is holding a fundraising gala in Newburyport, Massachusetts, this month to help advance a clinical trial. “When we received Talia’s…

Researchers have identified molecular consequences of mutations in the MORC2 gene — one of the genes that may cause Charcot-Marie Tooth (CMT) disease. The mutations, researchers at the University of Cambridge in the U.K. showed, cause alterations in what is known as epigenetic silencing, which is a mechanism for…